Objectives: (1) To develop a clinically useful model with which dermatologists can understand the potential uses of biologic therapy for psoriasis and understand the potential differences among these ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Patients with psoriasis who were treated with phototherapy and biologics had a lower incidence of PsA than those treated with phototherapy alone.

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.